US · Healthcare · Biotechnology
EPS came in at -0.99 against a street estimate of -0.97 — a miss of 2.1%.
Analysts rate LENZ Therapeutics Inc a buy (4 buy, 2 hold, 0 sell out of 6) with an average price target of $18.67.
MIXED VIZZ showed accelerating commercial momentum, but LENZ is restructuring around consumer marketing, cutting costs, and managing CEO succession while remaining unprofitable. Q3 FY26 VIZZ held 94% U.S. presbyopia eye-drop market share based on 2026 Symphony data; 11 international regulatory submissions were under review. Analysts focused on telehealth growth, advertising conversion, refill behavior, restructuring, profitability and CEO succession. Management emphasized rapid telehealth conversion, continued channel growth and cost reduction, while avoiding profitability guidance. 2026-10-29…
Full summary in the app.
| Fund | Stake |
|---|---|
| RA Capital Management, LLC | 13.30% |
| Alpha Wave Global LP | 11.50% |
| FMR Inc | 11.33% |
| Versant Venture Management LLC | 8.46% |
| BlackRock Inc | 7.29% |
| Squarepoint Ops LLC | 5.56% |
| Aberdeen Group PLC | 4.93% |
| Millennium Management LLC | 4.80% |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for LENZ Therapeutics Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.